Product/Composition:- | Liraglutide subcutaneous injection |
---|---|
Strength:- | 6 mg/mL solution |
Form:- | Subcutaneous injection/Pre filled Pen |
Reference Brands:- | Victoza(US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Liraglutide is a GLP-1 receptor agonist that mimics incretin hormones, stimulating insulin secretion, suppressing glucagon release, and delaying gastric emptying. Benefits include improved glycemic control in type 2 diabetes and weight loss (obesity management). It also reduces cardiovascular risk in high-risk patients. Administered once daily for convenience.
Liraglutide injection, approved by both the FDA and EMA, is prescribed for type 2 diabetes, weight management, and cardiovascular risk reduction. Marketed under brand names like Victoza® and Saxenda®, it requires a prescription and proper medical supervision. In the U.S., it carries a boxed warning for thyroid C-cell tumors, while the EU mandates PSURs and risk management plans. Cold-chain storage and pharmacovigilance are required in both regions. For regulatory-compliant sourcing and global distribution of liraglutide injection, visit PharmaTradz.com.